Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?

Autor: Wagar MK; Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: mwagar@wisc.edu., Sobecki JN; Division of Gynecologic Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Chandereng T; Department of Biostatistics, Columbia University, New York, NY, USA., Hartenbach EM; Division of Gynecologic Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Wallace SK; Division of Gynecologic Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2021 Sep; Vol. 162 (3), pp. 751-755. Date of Electronic Publication: 2021 Jun 17.
DOI: 10.1016/j.ygyno.2021.06.011
Abstrakt: Objectives: Minimally invasive surgery (MIS) is increasingly utilized for gynecologic cancers. While incidence of venous thromboembolism (VTE) after MIS is low, some guidelines recommend extended chemoprophylaxis for these patients undergoing MIS. Our objectives were to determine incidence of postoperative VTE in patients undergoing MIS, evaluate differences in the incidence by MIS modality and assess the need for extended chemoprophylaxis.
Methods: We conducted a retrospective cohort study including all patients undergoing MIS (robot-assisted, multi-port laparoscopy, single-port laparoscopy) for gynecologic cancers between January 2014 and December 2018 at our institution. Demographic and perioperative variables were collected. Patients <18 years, with benign pathology, or on preoperative anticoagulation were excluded. Chi-square, Fisher's exact test, and one-way ANOVA were performed to determine risk factors related to VTE occurrence.
Results: We identified 806 patients who underwent MIS with median age 61. Most had Stage I disease (81.5%) and uterine cancer (81.5%). Five VTE events occurred within 90 days following surgery (0.6%). Incidence of 90-day VTE did not differ between MIS modalities (p = 0.6). Patients with longer OR times (p = 0.004) were more likely to experience VTE. Age, smoking status, BMI, type of cancer and stage were not significant risk factors for VTE.
Conclusions: The incidence of postoperative VTE in patients with gynecologic cancers undergoing MIS is low and does not appear to differ by MIS modality. Given the very low incidence of postoperative VTE, extended chemoprophylaxis is unlikely to benefit patients with gynecologic malignancies undergoing MIS procedures.
Competing Interests: Declaration of Competing Interest The authors report no conflicts of interest of financial disclosures.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: